Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

被引:65
|
作者
Bahit, M. Cecilia [1 ]
Lopes, Renato D. [2 ]
Wojdyla, Daniel M. [2 ]
Held, Claes [3 ]
Hanna, Michael [4 ]
Vinereanu, Dragos [5 ]
Hylek, Elaine M. [6 ]
Verheugt, Freek [7 ]
Goto, Shinya [8 ]
Alexander, John H. [2 ]
Wallentin, Lars [3 ]
Granger, Christopher B. [2 ]
机构
[1] INECO, Neurociencias Orono Rosario, Santa Fe, NM, Argentina
[2] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[3] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Med & Pharm Carol Davila, Bucharest, Romania
[6] Boston Univ, Med Ctr, Boston, MA USA
[7] Onze Lieve Vrouwe Gasthuis OLVG, Heartctr, Amsterdam, Netherlands
[8] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
关键词
HEMORRHAGE; DABIGATRAN; THERAPY; STROKE; RISK;
D O I
10.1136/heartjnl-2016-309901
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective We describe the incidence, location and management of non-major bleeding, and assess the association between non-major bleeding and clinical outcomes in patients with atrial fibrillation (AF) receiving anticoagulation therapy enrolled in Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). Methods We included patients who received >= 1 dose of study drug (n= 18 140). Non-major bleeding was defined as the first bleeding event considered to be clinically relevant non-major (CRNM) or minor bleeding, and not preceded by a major bleeding event. Results Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Like major bleeding, non-major bleeding was less frequent with apixaban (6.4 per 100 patient-years) than warfarin (9.4 per 100 patient-years) (adjusted HR 0.69, 95% CI 0.63 to 0.75). The most frequent sites of non-major bleeding were haematuria (16.4%), epistaxis (14.8%), gastrointestinal (13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%). Medical or surgical intervention was similar among patients with non-major bleeding on warfarin versus apixaban (24.7% vs 24.5%). A change in antithrombotic therapy (58.6% vs 50.0%) and permanent study drug discontinuation (5.1% (61) vs 3.6% (30), p=0.10) was numerically higher with warfarin than apixaban. CRNM bleeding was independently associated with an increased risk of overall death (adjusted HR 1.70, 95% CI 1.32 to 2.18) and subsequent major bleeding (adjusted HR 2.18, 95% CI 1.56 to 3.04). Conclusions In ARISTOTLE, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. CRNM bleeding was independently associated with a higher risk of death and subsequent major bleeding. Our results highlight the importance of any severity of bleeding in patients with AF treated with anticoagulation therapy and suggest that non-major bleeding, including minor bleeding, might not be minor.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 50 条
  • [31] Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation
    Carnicelli, Anthony P.
    Al-Khatib, Sana M.
    Xavier, Denis
    Dalgaard, Frederik
    Merrill, Peter D.
    Wojdyla, Daniel M.
    Lewis, Basil S.
    Hanna, Michael
    Alexander, John H.
    Lopes, Renato D.
    Wallentin, Lars
    Granger, Christopher B.
    [J]. HEART, 2021, 107 (09) : 713 - 720
  • [32] Apixaban versus warfarin in Patients with Atrial Fibrillation in relation to Prior Warfarin Use: Insights from the ARISTOTLE trial
    Garcia, David A.
    Alexander, John H.
    Lopes, Renato D.
    Thomas, Laine
    Yang, Hongqiu
    Ansell, Iack
    Commerford, Patrick
    Flaker, Greg
    Lanas, Fernando
    Mohan, Puneet
    Vinereanu, Dragos
    Xavier, Denis
    Granger, Christopher
    Wallentin, Lars
    [J]. CIRCULATION, 2012, 126 (21)
  • [33] Relationship of Warfarin and Apixaban with Vascular Function in Patients with Atrial Fibrillation
    Junejo, Rehan T.
    Gupta, Dhiraj
    Snowdon, Richard L.
    Lip, Gregory Y. H.
    Fisher, James P.
    [J]. JOURNAL OF VASCULAR RESEARCH, 2024, 61 (02) : 59 - 67
  • [34] Risk of Stroke and Major Bleeding for Dabigatran, Rivaroxaban, and Warfarin Compared to Apixaban Among Non-Valvular Atrial Fibrillation Patients in the United States Medicare Population
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Dina, Oluwaseyi
    Le, Hannah
    Rosenblatt, Lisa
    Liu, Xianchen
    Mardekian, Jack
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    [J]. CIRCULATION, 2017, 136
  • [35] Real-world comparisons of major bleeding risk and major bleeding-related hospitalization costs among elderly non-valvular atrial fibrillation patients newly initiated on apixaban or warfarin
    Kamble, S.
    Keshishian, A.
    Pan, X.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 496 - 496
  • [36] Ximelagatran versus warfarin: A comparison of bleeding outcomes in patients with nonvalvular atrial fibrillation
    Douketis, JD
    Arneklev, K
    Goldhaber, S
    Spandorfer, J
    Halperin, F
    Horrow, J
    [J]. BLOOD, 2004, 104 (11) : 489A - 489A
  • [37] Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin
    Burgess, S.
    Crown, N.
    Louzada, M. L.
    Dresser, G.
    Kim, R. B.
    Lazo-Langner, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (09) : 1647 - 1654
  • [38] Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [39] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN FRAIL PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Turpie, Alexander
    Bunz, Thomas J.
    Sood, Nitesh
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 290 - 290
  • [40] APIXABAN VERSUS WARFARIN FOR PATIENTS WITH RECENT ONSET ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE TRIAL
    Guimaraes, Patricia
    Alexander, John
    Wojdyla, Daniel
    Thomas, Laine
    Alings, Marco
    Flaker, Greg
    Al-Khatib, Sana
    Hanna, Michael
    Wallentin, Lars
    Granger, Christopher
    Lopes, Renato
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 691 - 691